购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

LIT927

Rating icon 很棒
产品编号 T5207Cas号 2172879-52-4
别名 LIT-927, LIT 927

LIT927 (LIT-927) 是一种具有口服活性的 CXCL12 中性配体(对于 CXCL12 与 CXCR4 的结合,Ki:267 nM)。

LIT927
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

LIT927

Rating icon 很棒
纯度: 99.73%
产品编号 T5207 别名 LIT-927, LIT 927Cas号 2172879-52-4

LIT927 (LIT-927) 是一种具有口服活性的 CXCL12 中性配体(对于 CXCL12 与 CXCR4 的结合,Ki:267 nM)。

规格价格库存数量
1 mg¥ 248现货
2 mg¥ 355现货
5 mg¥ 579现货
10 mg¥ 892现货
25 mg¥ 1,590现货
50 mg¥ 2,430现货
100 mg¥ 3,560现货
500 mg¥ 7,690现货
1 mL x 10 mM (in DMSO)¥ 637现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"LIT927"的相关化合物库

选择批次:
纯度:99.73%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
LIT927 (LIT-927) is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
靶点活性
CXCL12:267 nM (Ki)
体外活性
LIT-927 at 10 μM is able to inhibit the increase in intracellular calcium concentration in EGFP-CXCR4+ HEK cells in response to CXCL12, while it has no effect on calcium responses triggered by either CCL17 or CCL22 on EGFP-CCR4+ HEK cells, CCL5 on EGFP-CCR5+ HEK cells, or CCL2 on EGFPCCR2+ HEK cells [1].
体内活性
LIT-927 (350 μmol/kg) inhibited eosinophil infiltration by 54% and 55%. LIT-927 did not exhibit any side effects. In the same murine model of hypereosinophilia, LIT-927 (1400 μmol/kg, P.O.) shows a large and statistically reliable inhibition of eosinophil recruitment (62% inhibition) [1].
细胞实验
HEK EGFP-CXCR4-expressing cells were washed with phosphate-buffered saline (PBS) and detached in PBS-EDTA (5 mM) for 2 min at room temperature. Then cells were carefully resuspended in complete growth medium, pelleted by centrifugation at 320 × g for 5 min, and resuspended in HEPES buffer (137.5 mM NaCl, 6 mM KCl, 1.25 mM CaCl2, 1.25 mM MgCl2, 0.4 mM NaH2PO4, 5.6 mM glucose, 10 mM HEPES (pH 7.4) containing 0.1% BSA. Cells were used at a concentration of 10^6 cells/mL, then the cell suspension (1 mL) was transferred into a quartz cuvette. Time-based recordings of the fluorescence emitted at 510 nm (excitation at 470 nm) were performed at 21 °C using a Fluorolog 3 spectrofluorometer. Fluorescence binding measurements were initiated by adding at t = 150 s, 100 nM CXCL12-Texas Red (TR) to the 1 mL cell suspension. Binding of CXCL12-TR to EGFP-labeled CXCR4 was detected as a reversible decline of emission at 510 nm due to energy transfer from excited EGFP to TR. In the "neutraligand protocol", CXCL12-TR was preincubated for 1 h at room temperature with DMSO or various concentrations of each test compound. Then the premix was added (at t = 150 s), and fluorescence was recorded until equilibrium was reached (300 s). In the "antagonist protocol", DMSO or various concentrations of each test compound were added to EGFP-CXCR4-expressing cells at t = 50 s. Then CXCL12-Texas Red (100 nM) was added at t = 150 s, and fluorescence was recorded until equilibrium was reached (300 s). Dose-response curves of inhibition of CXCL12-TR binding were performed, and the inhibitory constants (Ki) of the different compounds were determined. T134 (20 μM), the CXCR4 receptor antagonist, was used as a control in both "neutraligand" and "antagonist" protocols.
动物实验
The activity of each compound was assessed in vivo in an 8 day model of allergic eosinophilic airway inflammation as described previously. Briefly, 9 week-old male Balb/c mice were sensitized by intraperitoneal injection of 50 μg of ovalbumin adsorbed on 2 mg of aluminum hydroxide in 0.1 mL of saline on days 0, 1, and 2. Mice were challenged intranasally [10 μg of OVA in 25 μL of saline (12.5 μL/nostril)] on days 5, 6, and 7. Control mice received intranasal administration of saline alone. Intranasal administrations were performed under anesthesia with intraperitoneal injection of ketamine (50 mg/kg) and xylazine (3.33 mg/kg). Food and water were supplied ad libitum. Two hours before each OVA or saline challenge, compounds in PBS/Cdx were administered intranasally (12.5 μL/nostril), intraperitoneally, or per os as indicated in the figure legends. Bronchoalveolar lavage (BAL) was performed 24 h after the last OVA or saline challenge as described. Mice were deeply anesthetized by intraperitoneal injection of ketamine (150 mg/kg) and xylazine (10 mg/kg). A plastic cannula was inserted into the trachea, and airways were lavaged by 10 instillations of 0.5 mL of ice-cold saline supplemented with 2.6 mM EDTA (saline-EDTA). BAL fluids were centrifuged (300g, 5 min, 4 °C) to pellet cells, and erythrocytes were lysed by hypotonic shock. Cells were resuspended in 500 μL of icecold saline-EDTA, and total cell counts were determined on a hemocytometer. Differential cell counts were assessed on cytological preparations spanning 250 000 cells/mL in ice-cold saline?EDTA, stained with Diff-Quick with counts of at least 400 cells. Counts were expressed as absolute cell numbers or percentage of inhibition of eosinophil recruitment.
别名LIT-927, LIT 927
化学信息
分子量328.75
分子式C17H13ClN2O3
CAS No.2172879-52-4
SmilesO=C1NC(=CC(=N1)C2=CC=C(Cl)C=C2)C3=CC(OC)=C(O)C=C3
密度no data available
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
H2O: Insoluble
DMSO: 45 mg/mL (136.88 mM), Sonication is recommended.
溶液配制表
1mg5mg10mg50mg
1 mM3.0418 mL15.2091 mL30.4183 mL152.0913 mL
5 mM0.6084 mL3.0418 mL6.0837 mL30.4183 mL
10 mM0.3042 mL1.5209 mL3.0418 mL15.2091 mL
20 mM0.1521 mL0.7605 mL1.5209 mL7.6046 mL
50 mM0.0608 mL0.3042 mL0.6084 mL3.0418 mL
100 mM0.0304 mL0.1521 mL0.3042 mL1.5209 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy LIT927 | purchase LIT927 | LIT927 cost | order LIT927 | LIT927 chemical structure | LIT927 in vivo | LIT927 in vitro | LIT927 formula | LIT927 molecular weight